Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.

doi:10.1016/j.jhep.2022.01.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.

Journal of hepatology - 1 May 2022

Sonneveld Milan J, Chiu Shao-Ming, Park Jun Yong, Brakenhoff Sylvia M, Kaewdech Apichat, Seto Wai-Kay, Tanaka Yasuhito, Carey Ivana, Papatheodoridi Margarita, van Bömmel Florian, Berg Thomas, Zoulim Fabien, Ahn Sang Hoon, Dalekos George N, Erler Nicole S, Höner Zu Siederdissen Christoph, Wedemeyer Heiner, Cornberg Markus, Yuen Man-Fung, Agarwal Kosh, Boonstra Andre, Buti Maria, Piratvisuth Teerha, Papatheodoridis George, Chen Chien-Hung, Maasoumy Benjamin

Abstract excerpt

BACKGROUND & AIMS: Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance in a subset of patients. However, predictors of HBsAg loss after NUC withdrawal remain ill-defined. METHODS: We studied predictors of HBsAg loss in a global cohort of HBeAg-negative patients with undetectable HBV DNA who discontinued long-term NUC therapy. Patients requiring retreatment after treatment cessation were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B Core Antigens

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Probability

Source

Open in PubMed

Identifiers

PMID: 35092743
DOI: 10.1016/j.jhep.2022.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.PMID 35092743Read ↗

Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.Semantic proximity Read ↗

Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection.Semantic proximity Read ↗

Predictive Factors for HBsAg Loss in Chronic HBeAg-Negative Hepatitis B Virus Infection: Insights From a 5-Year French Cohort.Semantic proximity Read ↗

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.Semantic proximity Read ↗

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.Semantic proximity Read ↗

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.Semantic proximity Read ↗

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Semantic proximity Read ↗

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.Semantic proximity Read ↗

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.Semantic proximity Read ↗

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.Semantic proximity Read ↗

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.Semantic proximity Read ↗

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.